NOV 6 AADPAC

Results Wire: US FDA Advisory Committee Unanimously Supports Merck’s Proposed Reversal Agent to Neuromuscular Blockade, Bridion (Sugammadex) – NOV 6, 2015 (AADPAC)

On Friday, November 6, 2015, the Anesthetic and Analgesic Drugs Advisory Committee (AADPAC) unanimously supported, by a vote of 14-Yes to 0-No, with no abstentions, the safety and efficacy of Merck’s sugammadex sodium injection, submitted under NDA 022225, for the proposed indication of reversal of moderate or deep neuromuscular blockade induced by rocuronium or vecuronium.

See the SAC Tracker report